This finding is important, as the clinical trial of the HIV-1 vaccine ALVAC/AIDSVAX (RV144), despite being only about 30% effective, did not impact viral load or CD4+ cell counts in vaccinated individuals who became infected [63]; however, upon further analysis, it was reported that ADCC may have contributed to the ~30% protection reported in the trial because of a reduced risk of infection in vaccinated individuals that had lower IgA titers [64]. Here, CD79A is linked to infection.